Chimerix Inc CMRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EST
9.81UNCH (UNCH)
Volume
9,555
Close
9.81quote price arrow down-0.86 (-8.06%)
Volume
1,074,168
52 week range
1.19 - 11.57

...

Loading . . .

KEY STATS

  • Open10.36
  • Day High10.79
  • Day Low9.54
  • Prev Close10.67
  • 52 Week High11.57
  • 52 Week High Date02/17/21
  • 52 Week Low1.19
  • 52 Week Low Date03/19/20
  • Market Cap747.13M
  • Shares Out76.16M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta1.68
  • 1 Year % Change427.42

RATIOS/PROFITABILITY

  • EPS (TTM)-0.57
  • P/E (TTM)-17.19
  • Fwd P/E (NTM)-8.08
  • EBITDA (MRQ)-36.835M
  • ROE (MRQ)-36.23%
  • Revenue (MRQ)11.02M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-320.81%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Chimerix Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential...
Martha Demski
Chairman
Michael Sherman
President
Michael Andriole
Chief Financial Officer
Address
2505 Meridian Pkwy Ste 100
Durham, NC
27713-2288
United States